



CPT® Editorial Summary of Panel Actions February 2022 Electronic Meeting

CPT® Editorial Summary of Panel Actions February 2022

Please be aware that this action is a reflection of the discussion at the most recent telephonic Panel meeting.

The following approved code 0054A is effective from October 29, 2021.

The SARS-CoV-2 Vaccine product CPT code and immunization CPT codes can be found on the [AMA Website](#).

Name	Code #	Description of Editorial Panel Action	Effective Date
Immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only	#●0081A #●0082A	Accepted addition of codes 0081A, 0082A for immunization administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine only. Each administration code is specific to each individual vaccine product (eg, 91308); accepted revision of Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) Vaccines, a quick reference guide to showcase the coding structure for SARS-CoV-2 vaccine CPT reporting, to include codes 0081A, 0082A; and accepted revision of the guidelines in the Medicine Services, Immunization Administration for Vaccines/Toxoids, and the Vaccines, Toxoid subsections.	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines	#↗●91308	Accepted addition of code 91308 to report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines; accepted revision of Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) Vaccines, a quick reference guide to showcase the coding structure for SARS-CoV2 vaccine CPT reporting, to include code 91308; and accepted revision of the guidelines in the Medicine Services, Immunization Administration for Vaccines/Toxoids, and the Vaccines, Toxoid subsections.	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration